Biolex Therapeutics Enters into Agreement to Acquire Full Locteron® Commercial Rights
Biolex Therapeutics, Inc. announced that it has entered into an agreement with OctoPlus N.V. to acquire OctoPlus' 50 percent share of commercial rights to the Locteron product candidate for hepatitis C.... [more]
